Benzinga · Nov 11, 2026
Piper Sandler Maintains Overweight on Palisade Bio, Lowers Price Target to $16
Piper Sandler analyst Yasmeen Rahimi maintains Palisade Bio (NASDAQ:PALI) with a Overweight and lowers the price target from $25 to $16.
NASDAQ · PALI
Healthcare · Biotechnology
$1.12
Down-$0.09 (-8.04%)
Updated Nov 17, 2026, 1:36 AM
SID Score
3.5/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · PALI
1M range · 20 trading sessions · Daily adjusted prices
Prices through Nov 13, 2026
PALI closed at $1.12 after 20 trading sessions, down 16.42% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 13, 2026 | $1.15 | $1.15 | $1.08 | $1.12 | 1.46M |
| Nov 12, 2026 | $1.16 | $1.175 | $1.13 | $1.14 | 985.37K |
| Nov 11, 2026 | $1.11 | $1.185 | $1.11 | $1.17 | 2.97M |
| Nov 10, 2026 | $1.18 | $1.20 | $1.11 | $1.13 | 1.62M |
| Nov 9, 2026 | $1.16 | $1.23 | $1.145 | $1.19 | 1.41M |
| Nov 6, 2026 | $1.14 | $1.18 | $1.10 | $1.13 | 2.03M |
| Nov 5, 2026 | $1.22 | $1.225 | $1.10 | $1.16 | 2.6M |
| Nov 4, 2026 | $1.26 | $1.30 | $1.21 | $1.25 | 2.02M |
| Nov 3, 2026 | $1.14 | $1.245 | $1.13 | $1.23 | 18.65M |
| Nov 2, 2026 | $1.20 | $1.20 | $1.08 | $1.12 | 3.07M |
| Oct 30, 2026 | $1.18 | $1.20 | $1.115 | $1.16 | 3.09M |
| Oct 29, 2026 | $1.20 | $1.25 | $1.15 | $1.19 | 3.51M |
| Oct 28, 2026 | $1.22 | $1.22 | $1.10 | $1.19 | 15.12M |
| Oct 27, 2026 | $1.22 | $1.255 | $1.17 | $1.20 | 6.01M |
| Oct 26, 2026 | $1.33 | $1.35 | $1.21 | $1.23 | 1.7M |
| Oct 23, 2026 | $1.35 | $1.37 | $1.28 | $1.33 | 1.33M |
| Oct 22, 2026 | $1.38 | $1.41 | $1.349 | $1.35 | 1.11M |
| Oct 21, 2026 | $1.44 | $1.46 | $1.39 | $1.40 | 1.43M |
| Oct 20, 2026 | $1.39 | $1.48 | $1.335 | $1.43 | 2.82M |
| Oct 19, 2026 | $1.41 | $1.46 | $1.32 | $1.34 | 1.84M |
The latest Smart Investors Daily articles mentioning PALI.
Company
Market Activity
Research & News
PALI research
Company profile and research snapshot.
Palisade Bio Inc is a clinical-stage biopharma company focused on identifying and developing therapeutics that protect the integrity of the intestinal barrier. Its portfolio consists of a PALI-2108 for the treatment of IBD, including UC and CD, and is researching PALI-1908.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Nov 11, 2026 | Piper Sandler | Overweight | — |
| Nov 11, 2026 | HC Wainwright & Co. | Buy | — |
| Oct 13, 2026 | HC Wainwright & Co. | Buy | — |
| Oct 9, 2026 | Raymond James | Outperform | — |
| Sep 23, 2026 | HC Wainwright & Co. | Buy | — |
No generated briefing is available yet.
Benzinga · Nov 11, 2026
Piper Sandler analyst Yasmeen Rahimi maintains Palisade Bio (NASDAQ:PALI) with a Overweight and lowers the price target from $25 to $16.
Benzinga · Nov 11, 2026
HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Palisade Bio (NASDAQ:PALI) with a Buy and lowers the price target from $7 to $5.
Yahoo · Nov 10, 2026
First Patient Dosed in Global Phase 2b ASCENTRA-UC Trial; Topline Results Expected in Q4 2027 FDA Clearance Received for Phase 2a ASCENTRA-CD Trial; Initiation of Enrollment Targeted for Q1 2027 New Clinical and Translational Data Presented at ACG and UEG Week 2026 Highlight PALI-2108's Targeted Profile$113.6 Million in Cash and Cash Equivalents as of September 30, 2026 Denver, CO, Nov. 10, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a clinical-stage
Benzinga · Nov 10, 2026
Palisade Bio (NASDAQ:PALI) reported quarterly losses of $(0.07) per share which missed the analyst consensus estimate of $(0.06) by 16.67 percent. This is a 81.58 percent increase over losses of $(0.38) per share from
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.


The latest Smart Investors Daily articles mentioning PALI.